Mirna Therapeutics Secures $34,500,000 Series C Funding Round
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=d4cb71a0-c3ec-44d8-a764-fdde3b6b363f&Preview=1 - Date
10/24/2012 - Company Name
Mirna Therapeutics - Mailing Address
2150 Woodward St. Austin, TX 78744 - Company Description
Mirna Therapeutics, Inc., traces its lineage back to Ambion, Inc., a privately held company that offered research reagents for RNA analysis. It was at Ambion where Mirna’s miRNA therapeutic research and development program began in 2002 when the first molecular biology tools were developed for studying miRNAs. Ambion scientists started using these tools themselves to compare the miRNA expression patterns of tumor and normal adjacent tissue. - Website
http://www.mirnatherapeutics.com - Transaction Type
Venture Equity - Transaction Amount
$34,500,000 - Transaction Round
Series C - Proceeds Purposes
The funding will enable Mirna to advance its lead microRNA-based therapeutic product candidate MRX34 through human proof of concept studies. - M&A Terms
- Venture Investor
Sofinnova Ventures - Venture Investor
New Enterprise Associates - Venture Investor
Pfizer Venture Investments - Venture Investor
Osage Ventures - Venture Investor
Correlation Ventures
